发明名称 CDK9 KINASE INHIBITORS
摘要 Disclosed are compound of Formula (Ia),;;wherein R1A, R1, R2, R10, J, L, T, X, Y, and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions, comprising one or more compounds of Formula (Ia).
申请公布号 US2014275153(A1) 申请公布日期 2014.09.18
申请号 US201414207841 申请日期 2014.03.13
申请人 AbbVie Inc. 发明人 Lai Chunqiu;Tao Zhi-Fu;Woods Keith W.;Penning Thomas D.;Souers Andrew J.;Mastracchio Anthony;Miyashiro Julie M.;Tong Yunsong
分类号 C07D471/04;A61K31/437;C07D519/00 主分类号 C07D471/04
代理机构 代理人
主权项 1. A compound having Formula (Ia), or a pharmaceutically acceptable salt thereof, wherein the bond between Y and Z is a single or a double bond; wherein if the bond is a double bond then Y is N or CR3, and Z is N or CH; wherein if the bond is a single bond, then Y is CH2 and Z is CH2; J, X, and T are each independently N or CR3; R3 is selected from the group consisting of: H, C1-C6 alkyl, halo, CN, and C(N)OR3A; R3A is C1-C5 alkyl; L is absent or is a C1-C5 alkylene; R1A is H, C1-C6 alkyl, CN, or halo; R2 is H, phenyl, a 4 to 7 membered heterocycloalkyl, or a five to six membered heteroaryl; each of which may substituted with one to three substituents selected from the group consisting of: OR11, SR12, S(O)R13, SO2R13, C(O)R14, CO(O)R14, OC(O)R14, NH2, NHR15, NR16R17, NHC(O)R14, NR16C(O)R14, NHS(O)2R13, NR15S(O)2R13, NHC(O)OR14, NR15C(O)OR14, NHC(O)NH2, NHC(O)NHR15, NHC(O)NR16R17, NR15C(O)NHR16, NR15C(O)NR16R17, C(O)NH2, C(O)NHR15, C(O)NR16R17, C(O)NR15SO2R13, SO2NH2, SO2NHR15, SO2NR16R17, OH, CN, halo, C1-C8 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, 5 to 7 membered heterocycloalkyl, 5 to 7 membered heterocycloalkenyl, C3-C10 cycloalkyl, and C5-C10 cycloalkenyl; wherein each R2 aryl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, heteroaryl, 5 to 7 membered heterocycloalkyl, and 5 to 7 membered heterocycloalkenyl may be substituted with one, two, or three substituents independently selected from the group consisting of: OR18, SR19, S(O)R20, SO2R20, C(O)R21, CO(O)R22, OC(O)R21, NH2, NHR23, NR24R25, NHC(O)R21, NR23C(O)R21, NHS(O)2R20, NR23S(O)2R20, NHC(O)OR22, NHC(O)NH2, NHC(O)NHR23, NHC(O)NR24R25, NR23C(O)NHR23, NR25C(O)NR24R25, C(O)NH2, C(O)NHR23, C(O)NR24R25, C(O)NR23SO2R20, SO2NH2, SO2NHR23SO2NR24R25, OH, CN, and halo; R1 is a cycloalkyl, cycloalkenyl, a heterocycloalkyl, or heterocycloalkenyl, each of which may be substituted with one to three substituents selected from the group consisting of: OR26, SR27, S(O)R28, SO2R28, C(O)R29, CO(O)R30, OC(O)R29, NH2, NHR31, NR32R33, NHC(O)R29, NR31C(O)R29, NHS(O)2R28, NR31S(O)2R28, NHC(O)OR30, NR31C(O)OR30, NHC(O)NH2, NHC(O)NHR31, NHC(O)NR32R33, NR31C(O)NHR32, NR31C(O)NR32R33, C(O)NH2, C(O)NHR31, C(O)NR32R33, C(O)NR31SO2R28, SO2NH2, SO2NHR31, SO2NR32R33, OH, CN, halo, C1-C8 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, 5 to 7 membered heterocycloalkyl, 5 to 7 membered heterocycloalkenyl, C3-C10 cycloalkyl, and C5-C10 cycloalkenyl; wherein each R1 C1-C8 alkyl, aryl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, heteroaryl, 5 to 7 membered heterocycloalkyl, and 5 to 7 membered heterocycloalkenyl may be substituted with one to three substituents independently selected from the group consisting of R34, OR34, SR35, S(O)R36, SO2R36C(O)R37, CO(O)R38, OC(O)R37, NH2, NHR39, NR40R41, NHC(O)R37, NR39C(O)R37, NHS(O)2R36, NR39S(O)2R36, NHC(O)OR38, NHC(O)NH2, NHC(O)NHR39, NHC(O)NR40R41, NR39C(O)NHR40, NR39C(O)NR40R41, C(O)NH2, C(O)NHR39, C(O)NR40R41, C(O)NR39SO2R36, SO2NH2, SO2NHR39, SO2NR40R41, OH, CN, and halo; R10 is H or halo; each of R11 to R41, are independently selected from the group consisting of: C1-C8 alkyl, aryl, heteroaryl, 5 to 7 membered heterocycloalkyl, 5 to 7 membered heterocycloalkenyl, C3-C10 cycloalkyl, and C5-C10 cycloalkenyl wherein each R11 to R41 C1-C8 alkyl, aryl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, heteroaryl, 5 to 7 membered heterocycloalkyl, and 5 to 7 membered heterocycloalkenyl may be substituted with one to three substituents independently selected from the group consisting of OR42, SR43, S(O)R44, SO2R44, C(O)R45, CO(O)R46, OC(O)R45, NH2, NHR47, NR48R49, NHC(O)R45, NR47C(O)R45, NHS(O)2R44, NR47S(O)2R44, C(O)NH2, C(O)NHR47, C(O)NR40R41, C(O)NR47SO2R44, SO2NH2, SO2NHR47, SO2NR48R49, OH, CN, and halo; and each of R42 to R49, are independently selected from the group consisting of: C1-C5 alkyl, aryl, heteroaryl, 5 to 7 membered heterocycloalkyl, 5 to 7 membered heterocycloalkenyl, C3-C10 cycloalkyl, and C5-C10 cycloalkenyl.
地址 North Chicago IL US